Fig. 4.

Glycolysis inhibition does not impair the humoral response to influenza immunization. 8–10-week-old B6 and TC mice were infected with PR8 influenza virus. 2DG treatment was initiated 2 weeks before infection and maintained until termination. CD4⁺ and CD8⁺ T cells were analyzed 10 d after infection. a Representative FACS plot (left) and percentage (right) of splenic influenza virus-specific CD4⁺ T cells (CD4⁺CD44⁺NP-Tet^pos). b, c Frequency and number of CD4⁺CD44⁺PD-1^hiPSGL-1^lo T_FH cells in PR8 virus-specific NP-Tet^posCD4⁺ T cells (b) and in total CD4⁺ T cells (c). Serum levels of PR8 NP-specific IgG1, IgG2b and IgG2c (d), and anti-dsDNA IgG (e) 30 d after low dose infection. f, g Frequency and number of IFNγ⁺ in total CD4⁺ T cells (f) and PR8 virus-specific NP-Tet^posCD4⁺ T cells (g) in the lung. h, i Analysis of NP-Tet^posCD8⁺ T cells in the lung: representative FACS plots (h), total number (i), frequency and number of SLEC (j) and MPEC (k) among these NP-Tet^posCD8⁺ T cells, and SLEC/MPEC ratio (l). Mean + s.e.m. of N = 3–8 mice per group compared with t tests. *P < 0.05 and **P < 0.01